Evidence map›Paper›PMID 40613943›Full record

ArticleFunctional & integrative genomics2025

iACP-DPNet: a dual-pooling causal dilated convolutional network for interpretable anticancer peptide identification.

Zimeng Zhang, Xin Wang, Wenhui Shang

Abstract read
PubMed Publisher
In one paragraph

Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zimeng ZhangSchool of Science, Dalian Maritime University, Dalian, 116026, China.
Xin WangSchool of Science, Dalian Maritime University, Dalian, 116026, China. xenawang@dlmu.edu.cn.
Wenhui ShangSchool of Science, Dalian Maritime University, Dalian, 116026, China.

Funding

National Natural Science Foundation of China 61803065
6 · The paper itself

Abstract

Anticancer peptides (ACPs) are acknowledged for their potential in cancer therapy, attributed to their safety, low side effects, and high target specificity. However, the discovery of ACPs is slowed by the high cost and labor-intensive nature of experimental validation, resulting in a limited number of confirmed ACPs. Although various computational methods have been proposed, existing models commonly suffer from three critical limitations: reliance on small-scale datasets, lack of interpretable feature learning mechanisms, and insufficient generalization capability. To address these challenges, this study constructs a larger and more diverse dataset by consolidating data from existing literature and databases, and proposes a novel deep learning predictive model named iACP-DPNet. The model utilizes the protein language model ProtBert with positional encoding to convert protein sequences into feature vectors, then applies a two-step feature selection process via LightGBM and MIC. The selected features undergo processing by a causal dilated convolution network. A dual-pooling mechanism is designed to enhance the model's ability to synergistically model local critical residues and global sequence contexts, integrating parallel GlobalAveragePooling and attention pooling layers. Compared to traditional single-pooling models (e.g., ACP‑MHCNN), this architecture significantly improves feature extraction capability. To understand the model's decision-making process, we employ t-SNE for visualizing key steps, ISM for interpreting sequence regions, and SHAP analysis for evaluating feature importance. These approaches significantly improve the model's interpretability. The model exhibits outstanding performances on the novel dataset, as evidenced by rigorous tenfold cross-validation. Achieving remarkable metrics-including Sp of 96.1%, Sn of 92.91%, Acc of 94.5% and MCC of 89.05%, it significantly outperforms all existing state-of-the-art methods in comparative analyses. Furthermore, to assess its generalizability, we evaluated iACP-DPNet on an additional dataset, where it outperformed other current models. In conclusion, the iACP-DPNet exhibits exceptional performance and generalizability, showcasing its advanced design and effectiveness in ACPs prediction. This research provides a robust and interpretable framework for advancing research in anticancer peptide discovery. HIGHLIGHTS: • We have established a larger and more diverse dataset for ACPs prediction, addressing the limitations of existing datasets and providing a robust foundation for model training and evaluation. • The implementation of a dual-pooling layer mechanism (GlobalAveragePooling and attention pooling) bolsters the model's capacity to learn diverse features, ultimately enhancing its prediction efficiency. • We employed t-SNE visualization and ISM-based interpretability analysis to provide insights into the model's decision-making process, highlighting key regions and amino acids critical for ACPs functionality. • The iACP-DPNet model demonstrates strong generalizability across diverse datasets, making it a reliable tool for ACPs prediction and potentially other peptide-related tasks.

Indexed as

Antineoplastic AgentsComputational BiologyDeep LearningPeptidesHumansAntineoplastic AgentsPeptidesAnticancer peptidesCausal dilated convolutionDeep learningFeature selectionProtBertT-SNE

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.